These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 10168356)
21. Efficacy of apraclonidine ophthalmic solution (iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma. Flach AJ Surv Ophthalmol; 1995; 40(1):84-5. PubMed ID: 8545811 [No Abstract] [Full Text] [Related]
22. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group. Stewart WC; Laibovitz R; Horwitz B; Stewart RH; Ritch R; Kottler M Arch Ophthalmol; 1996 Aug; 114(8):938-42. PubMed ID: 8694728 [TBL] [Abstract][Full Text] [Related]
23. Reduction of anterior-segment vascularity with preoperative topical apraclonidine 1%. Sii F; Todd B; Shah P; Chiang M J Cataract Refract Surg; 2006 Apr; 32(4):692-3. PubMed ID: 16698500 [No Abstract] [Full Text] [Related]
24. Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine. Geyer O; Schmidt KG; Pianka P; Neudorfer M; Lazar M Graefes Arch Clin Exp Ophthalmol; 2000 Feb; 238(2):149-52. PubMed ID: 10766284 [TBL] [Abstract][Full Text] [Related]
25. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents. Maus TL; Nau C; Brubaker RF Arch Ophthalmol; 1999 May; 117(5):586-91. PubMed ID: 10326954 [TBL] [Abstract][Full Text] [Related]
26. The effect of apraclonidine on the intraocular pressure of glaucoma patients following Nd:YAG laser posterior capsulotomy. Cullom RD; Schwartz LW Ophthalmic Surg; 1993 Sep; 24(9):623-6. PubMed ID: 7901828 [TBL] [Abstract][Full Text] [Related]
27. Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%. Barnes SD; Campagna JA; Dirks MS; Doe EA Ophthalmology; 1999 Oct; 106(10):2033-7. PubMed ID: 10519604 [TBL] [Abstract][Full Text] [Related]
28. Chronic use of apraclonidine decreases its moderation of post-laser intraocular pressure spikes. Chung HS; Shin DH; Birt CM; Kim C; Lee D; Levin DS; Hakimzadeh R; Juzych MS Ophthalmology; 1997 Nov; 104(11):1921-5. PubMed ID: 9373127 [TBL] [Abstract][Full Text] [Related]
29. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment. Greenfield DS; Liebmann JM; Ritch R J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305 [TBL] [Abstract][Full Text] [Related]
30. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers. Mungan NK; Wilson TW; Nischal KK; Koren G; Levin AV J AAPOS; 2003 Feb; 7(1):69-70. PubMed ID: 12690374 [TBL] [Abstract][Full Text] [Related]
31. Short-term clinical trial evaluating the efficacy of the combination of apraclonidine 0.5% solution and betaxolol 0.25% suspension. Lamberti G; Pignalosa B; Fusco R; Pignalosa G; Di Govanni A; Sebastiani A Acta Ophthalmol Scand Suppl; 1997; (224):20-1. PubMed ID: 9589713 [No Abstract] [Full Text] [Related]
32. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy. thoe Schwartzenberg GW; Buys YM Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912 [TBL] [Abstract][Full Text] [Related]
34. Brimonidine tartrate for the treatment of glaucoma. Oh DJ; Chen JL; Vajaranant TS; Dikopf MS Expert Opin Pharmacother; 2019 Jan; 20(1):115-122. PubMed ID: 30407890 [TBL] [Abstract][Full Text] [Related]
35. The rarity of clinically significant rise in intraocular pressure after laser peripheral iridotomy with apraclonidine. Lewis R; Perkins TW; Gangnon R; Kaufman PL; Heatley GA Ophthalmology; 1998 Dec; 105(12):2256-9. PubMed ID: 9855156 [TBL] [Abstract][Full Text] [Related]
36. Early intraocular pressure response to laser trabeculoplasty 180 degrees without apraclonidine versus 360 degrees with apraclonidine. Allf BE; Shields MB Ophthalmic Surg; 1991 Sep; 22(9):539-42. PubMed ID: 1682861 [TBL] [Abstract][Full Text] [Related]
37. Effects of topical administration of 0.5% apraclonidine on intraocular pressure, pupil size, and heart rate in clinically normal dogs. Miller PE; Nelson MJ; Rhaesa SL Am J Vet Res; 1996 Jan; 57(1):79-82. PubMed ID: 8720243 [TBL] [Abstract][Full Text] [Related]
38. Effectiveness of apraclonidine and acetazolamide in preventing postoperative intraocular pressure spikes after extracapsular cataract extraction. Feist RM; Palmer DJ; Fiscella R; Ernest JT; Tripathi R; Torczynski E; Farber M J Cataract Refract Surg; 1995 Mar; 21(2):191-5. PubMed ID: 7791061 [TBL] [Abstract][Full Text] [Related]
39. Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy. Yuen NS; Cheung P; Hui SP Jpn J Ophthalmol; 2005; 49(2):89-92. PubMed ID: 15838723 [TBL] [Abstract][Full Text] [Related]
40. Short-term effect of apraclonidine on intraocular pressure in glaucoma patients receiving timolol and pilocarpine. Yüksel N; Elibol O; Caglar Y; Alçelik T Ophthalmologica; 1997; 211(6):354-7. PubMed ID: 9380353 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]